IP News Federal Circuit Reverses Teva Headache Patent Invalidity, Distinguishing Amgen on §112 Written Description and Enablement
The U.S. Court of Appeals for the Federal Circuit issued a precedential opinion on April 16, 2026, reversing a judgment ...